A 2024 pooled analysis of long-term outcomes from three clinical trials explored the durability of teprotumumab in individuals with thyroid eye disease (TED). The collective data involved 112 patients who completed seven or eight infusions of teprotumumab within the Phase 2, Phase 3 OPTIC, and OPTIC-X (see Table 1) studies. Clinical endpoints, including a reduction in Clinical Activity Score (CAS) by ≥2 points, improvements in proptosis (≥2 mm reduction), diplopia (≥1 Gorman grade), quality of life (GO-QoL), and overall response (proptosis + CAS improvement), were evaluated over an extended follow-up period. Data were assessed at multiple time points, from the study baseline to week 24 (therapy period) and beyond, with the longest follow-up extending to 99 weeks. Key findings demonstrated a sustained response in inflammatory activity and ophthalmic outcomes, with 91.2% of patients achieving CAS response and 89.5% reporting improvements in the composite European Group of Graves’ Orbitopathy outcome at 72 weeks. Proptosis response was maintained in 67.9% of participants, with a mean reduction of 2.68 mm at week 72, while 72.9% exhibited diplopia improvement. Quality-of-life measures reflected clinically meaningful gains, with a mean increase of 15.22 points in GO-QoL scores at 72 weeks. Notably, 82% of participants did not require additional TED-specific therapies (e.g., steroids, surgeries) up to 99 weeks. Adverse events were consistent with prior reports and predominantly mild to moderate, with no new safety signals identified during follow-up. These results underscore the prolonged benefits of teprotumumab on clinical and patient-reported outcomes in moderate-to-severe TED, highlighting its potential as a durable therapeutic strategy, including when used with a second course following initial nonresponse or disease flare. [1]